文献速递淋巴瘤

DNA甲基化在慢性淋巴细胞白血病患者中的临床意义:来自3项英国临床试验的结果

Clinical significance of DNA methylation in chronic lymphocytic leukemia patients: results from 3 UK clinical trials.
PubMed 文献 · Blood Adv · 2019-01-01

该研究纳入3项英国化疗及化学免疫治疗临床试验中的605例初治慢性淋巴细胞白血病患者,通过焦磷酸测序和微阵列分析将其分为n-CLL、i-CLL和m-CLL三个表观遗传亚组。

要点

  • DNA甲基化可将初治CLL分为n-CLL、i-CLL和m-CLL三个表观遗传亚组。

核心结论

  • 在3项英国一线CLL临床试验患者中,m-CLL表观遗传亚组是生存延长的独立标志物,可能有助于识别化学免疫治疗后生存期延长的患者。

研究设计与样本

  • 研究纳入3项英国化疗和化学免疫治疗临床试验中的605例初治CLL患者,使用焦磷酸测序和微阵列分析进行DNA甲基化分类并开展生存分析。

主要发现

  • 在IGHV未突变病例中,n-CLL、i-CLL和m-CLL分别占80%(245/305)、17%(53/305)和2%(7/305)。
  • 在IGHV突变病例中,n-CLL、i-CLL和m-CLL分别占9%(19/216)、50%(108/216)和41%(89/216)。

临床怎么用

  • DNA甲基化分型可用于初治CLL患者的预后分层,m-CLL提示化学免疫治疗后生存期可能延长。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Chronic lymphocytic leukemia patients with mutated immunoglobulin heavy-chain genes (IGHV-M), particularly those lacking poor-risk genomic lesions, often respond well to chemoimmunotherapy (CIT). DNA methylation profiling can subdivide early-stage patients into naive B-cell-like CLL (n-CLL), memory B-cell-like CLL (m-CLL), and intermediate CLL (i-CLL), with differing times to first treatment and overall survival. However, whether DNA methylation can identify patients destined to respond favorably to CIT has not been ascertained. We classified treatment-naive patients (n = 605) from 3 UK chemo and CIT clinical trials into the 3 epigenetic subgroups, using pyrosequencing and microarray analysis, and performed expansive survival analysis. The n-CLL, i-CLL, and m-CLL signatures were found in 80% (n = 245/305), 17% (53/305), and 2% (7/305) of IGHV-unmutated (IGHV-U) cases, respectively, and in 9%, (19/216), 50% (108/216), and 41% (89/216) of IGHV-M cases, respectively. Multivariate Cox proportional analysis identified m-CLL as an independent prognostic factor for overall survival (hazard ratio [HR], 0.46; 95% confidence interval [CI], 0.24-0.87; P = .018) in CLL4, and for progression-free survival (HR, 0.25; 95% CI, 0.10-0.57; P = .002) in ARCTIC and ADMIRE patients. The analysis of epigenetic subgroups in patients entered into 3 first-line UK CLL trials identifies m-CLL as an independent marker of prolonged survival and may aid in the identification of patients destined to demonstrate prolonged survival after CIT.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Wojdacz TK, Amarasinghe HE, Kadalayil L, et al. Clinical significance of DNA methylation in chronic lymphocytic leukemia patients: results from 3 UK clinical trials. Blood Adv. 2019. PMID: 31434681. doi:10.1182/bloodadvances.2019000237

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。